The ARMC6 Knockout HeLa Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population generated from the HeLa cell line for functional study of the ARMC6 gene. This heterogeneous pool of cells contains CRISPR/Cas9-mediated disruptions at the ARMC6 locus, providing a robust loss-of-function model without single-cell clone selection. The polyclonal format mitigates clonal artifacts and captures genetic diversity, making it suitable for population-level assays in cancer biology and signal transduction research.
HeLa cells are an immortalized HPV18-positive cell line derived from a cervical adenocarcinoma biopsy, widely used in biomedical research for protein expression studies, cancer research, and functional genomics. As a cervical cancer model of epithelial origin, HeLa cells provide a relevant context for investigating genes involved in tumorigenesis, cell adhesion, migration, and cytoskeletal dynamics.
ARMC6 encodes an armadillo repeat-containing protein that mediates protein?Cprotein interactions, likely functioning in signal transduction and cytoskeletal regulation. In the Wnt pathway, the armadillo protein beta-catenin interacts with TCF/LEF factors to regulate transcription, and ARMC6 is predicted to bind beta-catenin, importins, and APC, suggesting a role in modulating Wnt-responsive programs. ARMC6 may act downstream of proliferative signals or tether signaling complexes to actin, and its disruption can perturb networks critical for cellular architecture and proliferative signaling in HeLa cells.
In the HeLa cervical cancer background, ARMC6 knockout provides a platform to dissect its contributions to tumorigenic phenotypes. The presence of HPV18 oncoproteins allows systematic examination of the interplay between viral transformation and ARMC6 function. The polyclonal population enables assessment of bulk responses such as proliferation, migration, and invasion without clonal selection effects, and facilitates investigation of crosstalk with the Wnt?Cbeta-catenin axis, supporting identification of therapeutic vulnerabilities in cervical cancer.
This product is suited for diverse functional assays. Western blotting and co-immunoprecipitation validate ARMC6 loss and partner disruption; immunofluorescence visualizes altered localization of beta-catenin or cytoskeletal elements. Proliferation, migration, and invasion assays quantify phenotypic changes, and RNA-seq maps transcriptomic alterations. A beta-catenin reporter monitors Wnt activity. These applications support study of armadillo repeat proteins, protein interaction networks in cervical cancer, functional genomics screening, and drug target discovery. For technical support, contact Ascent Research.
